What is CereSpir?
CereSpir Inc. is a biopharmaceutical company dedicated to pioneering treatments for Parkinson's disease and other neurodegenerative conditions through its innovative immuno-neurology approach. The company's lead therapeutic agent, Itanapraced, is designed to target LRRK2 neurotoxicity and is the sole AICD inhibitor currently under development. CereSpir's strategic focus is on addressing the complex challenges of neurodegeneration, aiming to provide novel solutions for patients and the medical community.
How much funding has CereSpir raised?
CereSpir has raised a total of $500K across 1 funding round:
Private Equity
$500K
Private Equity (2016): $500K, investors not publicly disclosed
What's next for CereSpir?
With a major enterprise-level funding context and a recent strategic investment, CereSpir is positioned for significant advancement in its clinical development pipeline. The company's focus on Itanapraced, a novel therapeutic for neurodegenerative diseases, suggests a trajectory towards scaling operations and potentially advancing through later-stage clinical trials. This backing will likely fuel research and development efforts, aiming to validate its unique therapeutic mechanisms and expand its market presence in the competitive biopharmaceutical landscape.
See full CereSpir company page
